BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32217788)

  • 1. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.
    Kleerekooper I; Herbert MK; Kuiperij HB; Sato DK; Fujihara K; Callegaro D; Marignier R; Saiz A; Senel M; Tumani H; De Jong BA; Trip SA; Nakashima I; Verbeek MM; Petzold A
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):605-611. PubMed ID: 32217788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
    Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
    J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders.
    Wei Y; Chang H; Li X; Du L; Xu W; Cong H; Yao Y; Zhang X; Yin L
    Biomed Res Int; 2018; 2018():5381239. PubMed ID: 30426010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocytic damage in glial fibrillary acidic protein astrocytopathy during initial attack.
    Yang X; Huang Q; Yang H; Liu S; Chen B; Liu T; Yang J; Yao H; Lin S; Chen X; Zhuang H; Long Y; Gao C
    Mult Scler Relat Disord; 2019 Apr; 29():94-99. PubMed ID: 30690341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
    Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
    Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
    Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
    Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD
    Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
    Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
    Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients.
    Jasiak-Zatońska M; Michalak S; Osztynowicz K; Kozubski W; Kalinowska-Łyszczarz A
    Neurol Neurochir Pol; 2022; 56(4):308-317. PubMed ID: 35029294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
    Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
    Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.
    Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P
    Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica.
    Takano R; Misu T; Takahashi T; Izumiyama M; Fujihara K; Itoyama Y
    Tohoku J Exp Med; 2008 May; 215(1):55-9. PubMed ID: 18509235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
    Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
    Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.